Related references
Note: Only part of the references are listed.Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
Gaudensia Mutua et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
Zacchaeus Anywaine et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor
Alexander T. Baker et al.
SCIENCE ADVANCES (2019)
αvβ3 Integrin Is Required for Efficient Infection of Epithelial Cells with Human Adenovirus Type 26
Davor Nestic et al.
JOURNAL OF VIROLOGY (2019)
Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy
Brennetta J. Crenshaw et al.
BIOMEDICINES (2019)
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
Thomas P. Monath et al.
VACCINE: X (2019)
Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8(+) T cell responses against HPV16 oncoproteins
Nicolas Cuburu et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
EBOVAC-Salone: Lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country
Thomas Mooney et al.
CLINICAL TRIALS (2018)
Stability and suitability for storage and distribution of Ad26.ZEBOV/MVA-BN®-Filo heterologous prime-boost Ebola vaccine
Martinus A. H. Capelle et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2018)
Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys
Zi Han Kang et al.
JOURNAL OF VIROLOGY (2018)
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Dan H. Barouch et al.
LANCET (2018)
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates (vol 13, e0192312, 2018)
Benoit Callendret et al.
PLOS ONE (2018)
Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge
Freek Cox et al.
PLOS ONE (2018)
A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
Georgi Shukarev et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16-and HPV18-induced infections and disease
Selina Khan et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year
Rebecca L. Winslow et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Durability and correlates of vaccine protection against Zika virus in rhesus monkeys
Peter Abbink et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention
Lindsey R. Baden et al.
ANNALS OF INTERNAL MEDICINE (2016)
Safety and Immunogenicity of Novel Adenovirus Type 26-and Modified Vaccinia Ankara-Vectored Ebola Vaccines A Randomized Clinical Trial
Iain D. Milligan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys
Erica N. Borducchi et al.
NATURE (2016)
New drug on the horizon for treating adenovirus
William S. M. Wold et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Immunogenicity without Efficacy of an Adenoviral Tuberculosis Vaccine in a Stringent Mouse Model for Immunotherapy during Treatment
S. Anisah Alyahya et al.
PLOS ONE (2015)
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys
Dan H. Barouch et al.
SCIENCE (2015)
Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats
Myra N. Widjojoatmodjo et al.
VACCINE (2015)
Induction of HIV-1-Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans
Lindsey R. Baden et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Adenovirus Infections in Immunocompetent and Immunocompromised Patients
Thomas Lion
CLINICAL MICROBIOLOGY REVIEWS (2014)
Epidemiology of loss pregnancy
A. Delabaere et al.
JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION (2014)
Late Endosomal Trafficking of Alternative Serotype Adenovirus Vaccine Vectors Augments Antiviral Innate Immunity
Jeffrey E. Teigler et al.
JOURNAL OF VIROLOGY (2014)
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)
Lindsey R. Baden et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)
Dan H. Barouch et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Alternative Serotype Adenovirus Vaccine Vectors Elicit Memory T Cells with Enhanced Anamnestic Capacity Compared to Ad5 Vectors
Pablo Penaloza-MacMaster et al.
JOURNAL OF VIROLOGY (2013)
Low Seroprevalent Species D Adenovirus Vectors as Influenza Vaccines
Eric A. Weaver et al.
PLOS ONE (2013)
New insights into stability of recombinant adenovirus vector genomes in mammalian cells
Christina Rauschhuber et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2012)
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine
Nicole Frahm et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Adenovirus Serotype 26 Utilizes CD46 as a Primary Cellular Receptor and Only Transiently Activates T Lymphocytes following Vaccination of Rhesus Monkeys
Hualin Li et al.
JOURNAL OF VIROLOGY (2012)
Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys
Jeffrey E. Teigler et al.
JOURNAL OF VIROLOGY (2012)
Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
Cheng Cheng et al.
PLOS ONE (2012)
Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species
Roland Zahn et al.
PLOS ONE (2012)
Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge
Thomas W. Geisbert et al.
JOURNAL OF VIROLOGY (2011)
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations
Dan H. Barouch et al.
VACCINE (2011)
The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert
Katarina Radosevic et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae
H. Chen et al.
JOURNAL OF VIROLOGY (2010)
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials
T. Christopher Mast et al.
VACCINE (2010)
Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys
Jonatan Ersching et al.
VIROLOGY (2010)
Opportunities and challenges of developing thermostable vaccines
Dexiang Chen et al.
EXPERT REVIEW OF VACCINES (2009)
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults
Frances H. Priddy et al.
CLINICAL INFECTIOUS DISEASES (2008)
Episomal vectors for gene therapy
Anja Ehrhardt et al.
CURRENT GENE THERAPY (2008)
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
M. Juliana McElrath et al.
LANCET (2008)
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D
Peter Abbink et al.
JOURNAL OF VIROLOGY (2007)
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
Andrew T. Catanzaro et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells
M. Havenga et al.
JOURNAL OF GENERAL VIROLOGY (2006)
Acute meningoencephalitis caused by adenovirus serotype 26
Erik R. Dubberke et al.
JOURNAL OF NEUROVIROLOGY (2006)
Functions and mechanisms of action of the adenovirus E3 proteins
DL Lichtenstein et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2004)
Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination:: Efficient human cell infection and bypass of preexisting adenovirus immunity
R Vogels et al.
JOURNAL OF VIROLOGY (2003)
Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectors
MC Sprangers et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
Share Paper
